COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.
Ann Hematol
; 99(8): 1701-1707, 2020 Aug.
Article
in English
| MEDLINE | ID: covidwho-613171
ABSTRACT
COVID-19 pandemia is a major health emergency causing hundreds of deaths worldwide. The high reported morbidity has been related to hypoxia and inflammation leading to endothelial dysfunction and aberrant coagulation in small and large vessels. This review addresses some of the pathways leading to endothelial derangement, such as complement, HIF-1α, and ABL tyrosine kinases. This review also highlights potential targets for prevention and therapy of COVID-19-related organ damage and discusses the role of marketed drugs, such as eculizumab and imatinib, as suitable candidates for clinical trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Protein-Tyrosine Kinases
/
Endothelium, Vascular
/
Drug Delivery Systems
/
Coronavirus Infections
/
Hypoxia-Inducible Factor 1, alpha Subunit
/
Complement Inactivating Agents
/
Betacoronavirus
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Ann Hematol
Journal subject:
Hematology
Year:
2020
Document Type:
Article
Affiliation country:
S00277-020-04138-8
Similar
MEDLINE
...
LILACS
LIS